Cholesterol-independent suppression of lymphocyte activation, autoimmunity, and glomerulonephritis by apolipoprotein A-I in normocholesterolemic lupus-prone mice

Journal of Immunology

Volumn 195, Issue 10, 2015, Pages 4685-4698

  Black, Leland L ^a   Srivastava, Roshni ^a,d   Schoeb, Trenton R ^b   Moore, Ray D ^c   Barnes, Stephen ^c   Kabarowski, Janusz H ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13 HYDROXYOCTADECADIENOIC ACID; 9 HYDROXYOCTADECADIENOIC ACID; ALBUMIN; APOLIPOPROTEIN A1; CHOLESTEROL; CREATININE; FATTY ACID; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; 13-HYDROXY-9,11-OCTADECADIENOIC ACID; APOLIPOPROTEIN E; AUTOANTIBODY; LINOLEIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; GLOMERULONEPHRITIS; HELPER CELL; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; KNOCKOUT MOUSE; LIPID ANALYSIS; LYMPHOCYTE ACTIVATION; MASS FRAGMENTOGRAPHY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TRANSGENIC MOUSE; ANIMAL; BLOOD; C57BL MOUSE; CELL MOTION; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLISM; PATHOLOGY;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CELL MOVEMENT; CHOLESTEROL; DENDRITIC CELLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; LINOLEIC ACIDS; LIPOPROTEINS, HDL; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PPAR GAMMA; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 84958606742     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500806     Document Type: Article

References (68)

1. Lewis, G. F., and D. J. Rader. 2005. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96: 1221-1232.
2. Sorci-Thomas, M. G., and M. J. Thomas. 2012. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler. Thromb. Vasc. Biol. 32: 2561-2565.
3. Westerterp, M., A. E. Bochem, L. Yvan-Charvet, A. J. Murphy, N. Wang, and A. R. Tall. 2014. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ. Res. 114: 157-170.
4. Zhu, X., and J. S. Parks. 2012. New roles of HDL in inflammation and hematopoiesis. Annu. Rev. Nutr. 32: 161-182.
5. Navab, M., S. T. Reddy, G. M. Anantharamaiah, G. Hough, G. M. Buga, J. Danciger, and A. M. Fogelman. 2012. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J. Lipid Res. 53: 437-445.
6. Folcik, V. A., R. A. Nivar-Aristy, L. P. Krajewski, and M. K. Cathcart. 1995. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J. Clin. Invest. 96: 504-510.
7. Imaizumi, S., V. Grijalva, M. Navab, B. J. Van Lenten, A. C. Wagner, G. M. Anantharamiah, A. M. Fogelman, and S. T. Reddy. 2010. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more antiinflammatory HDL in mice. Drug Metab. Lett. 4: 139-148.
8. Wilhelm, A. J., M. Zabalawi, J. M. Grayson, A. E. Weant, A. S. Major, J. Owen, M. Bharadwaj, R. Walzem, L. Chan, K. Oka, et al. 2009. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler. Thromb. Vasc. Biol. 29: 843-849.
9. Bensinger, S. J., M. N. Bradley, S. B. Joseph, N. Zelcer, E. M. Janssen, M. A. Hausner, R. Shih, J. S. Parks, P. A. Edwards, B. D. Jamieson, and P. Tontonoz. 2008. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134: 97-111.
10. A-Gonzalez, N., S. J. Bensinger, C. Hong, S. Beceiro, M. N. Bradley, N. Zelcer, J. Deniz, C. Ramirez, M. Díaz, G. Gallardo, et al. 2009. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31: 245-258.
11. Feng, H., L. Guo, D. Wang, H. Gao, G. Hou, Z. Zheng, J. Ai, O. Foreman, A. Daugherty, and X. A. Li. 2011. Deficiency of scavenger receptor BI leads to impaired lymphocyte homeostasis and autoimmune disorders in mice. Arterioscler. Thromb. Vasc. Biol. 31: 2543-2551.
12. Yvan-Charvet, L., T. Pagler, E. L. Gautier, S. Avagyan, R. L. Siry, S. Han, C. L. Welch, N.Wang, G. J. Randolph, H.W. Snoeck, and A. R. Tall. 2010. ATPbinding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328: 1689-1693.
13. Watson, C. E., N. Weissbach, L. Kjems, S. Ayalasomayajula, Y. Zhang, I. Chang, M. Navab, S. Hama, G. Hough, S. T. Reddy, et al. 2011. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 52: 361-373.
14. Getz, G. S., and C. A. Reardon. 2014. The structure/function of apoprotein A-I mimetic peptides: an update. Curr. Opin. Endocrinol. Diabetes Obes. 21: 129-133.
15. Woo, J. M., Z. Lin, M. Navab, C. Van Dyck, Y. Trejo-Lopez, K. M. Woo, H. Li, L. W. Castellani, X. Wang, N. Iikuni, et al. 2010. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res. Ther. 12: R93.
16. Kiss, E., I. Seres, T. Tarr, Z. Kocsis, G. Szegedi, and G. Paragh. 2007. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1108: 83-91.
17. McMahon, M., J. Grossman, B. Skaggs, J. Fitzgerald, L. Sahakian, N. Ragavendra, C. Charles-Schoeman, K. Watson, W. K. Wong, E. Volkmann, et al. 2009. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 60: 2428-2437.
18. Srivastava, R., S. Yu, B. W. Parks, L. L. Black, and J. H. Kabarowski. 2011. Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice. Arthritis Rheum. 63: 201-211.
19. Rubin, E. M., B. Y. Ishida, S. M. Clift, and R. M. Krauss. 1991. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc. Natl. Acad. Sci. USA 88: 434-438.
20. Parks, B. W., R. Srivastava, S. Yu, and J. H. Kabarowski. 2009. ApoE-dependent modulation of HDL and atherosclerosis by G2A in LDL receptor-deficient mice independent of bone marrow-derived cells. Arterioscler. Thromb. Vasc. Biol. 29: 539-547.
21. Robbiani, D. F., R. A. Finch, D. Jäger, W. A. Muller, A. C. Sartorelli, and G. J. Randolph. 2000. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103: 757-768.
22. Kevil, C. G., M. J. Hicks, X. He, J. Zhang, C. M. Ballantyne, C. Raman, T. R. Schoeb, and D. C. Bullard. 2004. Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease. Am. J. Pathol. 165: 609-616.
23. He, X., T. R. Schoeb, A. Panoskaltsis-Mortari, K. R. Zinn, R. A. Kesterson, J. Zhang, S. Samuel, M. J. Hicks, M. J. Hickey, and D. C. Bullard. 2006. Deficiency of P-selectin or P-selectin glycoprotein ligand-1 leads to accelerated development of glomerulonephritis and increased expression of CC chemokine ligand 2 in lupus-prone mice. J. Immunol. 177: 8748-8756.
24. de Vries, B., J. Köhl, W. K. Leclercq, T. G. Wolfs, A. A. van Bijnen, P. Heeringa, and W. A. Buurman. 2003. Complement factor C5a mediates renal ischemiareperfusion injury independent from neutrophils. J. Immunol. 170: 3883-3889.
25. Parks, B. W., L. L. Black, K. A. Zimmerman, A. E. Metz, C. Steele, J. E. Murphy-Ullrich, and J. H. Kabarowski. 2013. CD36, but not G2A, modulates efferocytosis, inflammation, and fibrosis following bleomycin-induced lung injury. J. Lipid Res. 54: 1114-1123.
26. Young, S., E. Struys, and T. Wood. 2007. Quantification of creatine and guanidinoacetate using GC-MS and LC-MS/MS for the detection of cerebral creatine deficiency syndromes. Curr. Protoc. Hum. Genet. 54: 17.3.1-17.3.17.
27. Parks, B. W., G. P. Gambill, A. J. Lusis, and J. H. Kabarowski. 2005. Loss of G2A promotes macrophage accumulation in atherosclerotic lesions of low density lipoprotein receptor-deficient mice. J. Lipid Res. 46: 1405-1415.
28. Nordskog, B. K., J. W. Reagan, Jr., and R. W. St Clair. 1999. Sterol synthesis is up-regulated in cholesterol-loaded pigeon macrophages during induction of cholesterol efflux. J. Lipid Res. 40: 1806-1817.
29. Wang, Y., J. Sawashita, J. Qian, B. Zhang, X. Fu, G. Tian, L. Chen, M. Mori, and K. Higuchi. 2011. ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis. J. Lipid Res. 52: 1461-1470.
30. Basu, S. K., Y. K. Ho, M. S. Brown, D. W. Bilheimer, R. G. Anderson, and J. L. Goldstein. 1982. Biochemical and genetic studies of the apoprotein E secreted by mouse macrophages and human monocytes. J. Biol. Chem. 257: 9788-9795.
31. Gaidukov, L., and D. S. Tawfik. 2005. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44: 11843-11854.
32. Walsh, A., Y. Ito, and J. L. Breslow. 1989. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J. Biol. Chem. 264: 6488-6494.
33. Craft, J. E. 2012. Follicular helper T cells in immunity and systemic autoimmunity. Nat. Rev. Rheumatol. 8: 337-347.
34. Angeli, V., J. Llodrá, J. X. Rong, K. Satoh, S. Ishii, T. Shimizu, E. A. Fisher, and G. J. Randolph. 2004. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21: 561-574.
35. Sorci-Thomas, M. G., J. S. Owen, B. Fulp, S. Bhat, X. Zhu, J. S. Parks, D. Shah, W. G. Jerome, M. Gerelus, M. Zabalawi, and M. J. Thomas. 2012. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J. Lipid Res. 53: 1890-1909.
36. Waddington, E. I., K. D. Croft, K. Sienuarine, B. Latham, and I. B. Puddey. 2003. Fatty acid oxidation products in human atherosclerotic plaque: an analysis of clinical and histopathological correlates. Atherosclerosis 167: 111-120.
37. Navab, M., S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman. 2011. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8: 222-232.
38. Vaisar, T., S. Pennathur, P. S. Green, S. A. Gharib, A. N. Hoofnagle, M. C. Cheung, J. Byun, S. Vuletic, S. Kassim, P. Singh, et al. 2007. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117: 746-756.
39. Getz, G. S., and C. A. Reardon. 2009. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J. Lipid Res. 50(Suppl.): S156-S161.
40. Sontag, T. J., and C. A. Reardon. 2014. Polymorphisms of mouse apolipoprotein A-II alter its physical and functional nature. PLoS One 9: e88705.
41. Xie, C., R. Sharma, H. Wang, X. J. Zhou, and C. Mohan. 2004. Strain distribution pattern of susceptibility to immune-mediated nephritis. J. Immunol. 172: 5047-5055.
42. Wilhelm, A. J., M. Zabalawi, J. S. Owen, D. Shah, J. M. Grayson, A. S. Major, S. Bhat, D. P. Gibbs, Jr., M. J. Thomas, and M. G. Sorci-Thomas. 2010. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/-mice. J. Biol. Chem. 285: 36158-36169.
43. Zhang, Y., I. Zanotti, M. P. Reilly, J. M. Glick, G. H. Rothblat, and D. J. Rader. 2003. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108: 661-663.
44. Van Lenten, B. J., A. C.Wagner, C. L. Jung, P. Ruchala, A. J.Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, and A. M. Fogelman. 2008. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 49: 2302-2311.
45. Patricia, M. K., J. A. Kim, C. M. Harper, P. T. Shih, J. A. Berliner, R. Natarajan, J. L. Nadler, and C. C. Hedrick. 1999. Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19: 2615-2622.
46. Huber, J., A. Fürnkranz, V. N. Bochkov, M. K. Patricia, H. Lee, C. C. Hedrick, J. A. Berliner, B. R. Binder, and N. Leitinger. 2006. Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase. J. Lipid Res. 47: 1054-1062.
47. Limor, R., O. Sharon, E. Knoll, A. Many, G. Weisinger, and N. Stern. 2008. Lipoxygenase-derived metabolites are regulators of peroxisome proliferatoractivated receptor gamma-2 expression in human vascular smooth muscle cells. Am. J. Hypertens. 21: 219-223.
48. Wittwer, J., and M. Hersberger. 2007. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot. Essent. Fatty Acids 77: 67-77.
49. Nicolaou, A., C. Mauro, P. Urquhart, and F. Marelli-Berg. 2014. Polyunsaturated Fatty Acid-derived lipid mediators and T cell function. Front. Immunol. 5: 75.
50. Kiss, M., Z. Czimmerer, and L. Nagy. 2013. The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology. J. Allergy Clin. Immunol. 132: 264-286.
51. Choi, J. M., and A. L. Bothwell. 2012. The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol. Cells 33: 217-222.
52. Kidani, Y., and S. J. Bensinger. 2012. Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol. Rev. 249: 72-83.
53. Yang, X. Y., L. H. Wang, K. Mihalic, W. Xiao, T. Chen, P. Li, L. M. Wahl, and W. L. Farrar. 2002. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. J. Biol. Chem. 277: 3973-3978.
54. Kühn, H., and V. B. O'Donnell. 2006. Inflammation and immune regulation by 12/15-lipoxygenases. Prog. Lipid Res. 45: 334-356.
55. Harris, S. G., J. Padilla, L. Koumas, D. Ray, and R. P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends Immunol. 23: 144-150.
56. Natarajan, C., and J. J. Bright. 2002. Peroxisome proliferator-activated receptorgamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun. 3: 59-70.
57. Oxer, D. S., L. C. Godoy, E. Borba, T. Lima-Salgado, L. A. Passos, I. Laurindo, S. Kubo, D. F. Barbeiro, D. Fernandes, F. R. Laurindo, et al. 2011. PPARg expression is increased in systemic lupus erythematosus patients and represses CD40/CD40L signaling pathway. Lupus 20: 575-587.
58. Zhao, W., C. C. Berthier, E. E. Lewis, W. J. McCune, M. Kretzler, and M. J. Kaplan. 2013. The peroxisome-proliferator activated receptor-g agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus. Clin. Immunol. 149: 119-132.
59. Park, H. J., D. H. Kim, J. Y. Choi, W. J. Kim, J. Y. Kim, A. G. Senejani, S. S. Hwang, L. K. Kim, Z. Tobiasova, G. R. Lee, et al. 2014. PPARg negatively regulates T cell activation to prevent follicular helper T cells and germinal center formation. PLoS One 9: e99127.
60. Weinmann, A. S. 2014. Regulatory mechanisms that control T-follicular helper and T-helper 1 cell flexibility. Immunol. Cell Biol. 92: 34-39.
61. Hahn, B. H. 2010. Should antibodies to high-density lipoprotein cholesterol and its components be measured in all systemic lupus erythematosus patients to predict risk of atherosclerosis? Arthritis Rheum. 62: 639-642.
62. Wilhelm, A. J., and A. S. Major. 2012. Accelerated atherosclerosis in SLE: mechanisms and prevention approaches. Int. J. Clin. Rheumatol. 7: 527-539.
63. Tripi, L. M., S. Manzi, Q. Chen, M. Kenney, P. Shaw, A. Kao, F. Bontempo, C. Kammerer, and M. I. Kamboh. 2006. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum. 54: 1928-1939.
64. Rivera, J., R. L. Proia, and A. Olivera. 2008. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 8: 753-763.
65. Koch, A., J. Pfeilschifter, and A. Huwiler. 2013. Sphingosine 1-phosphate in renal diseases. Cell. Physiol. Biochem. 31: 745-760.
66. Catapano, A. L., A. Pirillo, F. Bonacina, and G. D. Norata. 2014. HDL in innate and adaptive immunity. Cardiovasc. Res. 103: 372-383.
67. Celhar, T., R. Magalhães, and A. M. Fairhurst. 2012. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol. Res. 53: 58-77.
68. DiDonato, J. A., K. Aulak, Y. Huang, M. Wagner, G. Gerstenecker, C. Topbas, V. Gogonea, A. J. DiDonato, W. H. Tang, R. A. Mehl, et al. 2014. Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J. Biol. Chem. 289: 10276-10292.